[go: up one dir, main page]

WO2012061239A3 - Novel vaccines against pandemic influenza virus a/h1n1 - Google Patents

Novel vaccines against pandemic influenza virus a/h1n1 Download PDF

Info

Publication number
WO2012061239A3
WO2012061239A3 PCT/US2011/058336 US2011058336W WO2012061239A3 WO 2012061239 A3 WO2012061239 A3 WO 2012061239A3 US 2011058336 W US2011058336 W US 2011058336W WO 2012061239 A3 WO2012061239 A3 WO 2012061239A3
Authority
WO
WIPO (PCT)
Prior art keywords
influenza virus
vaccines against
pandemic influenza
novel vaccines
against pandemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/058336
Other languages
French (fr)
Other versions
WO2012061239A2 (en
Inventor
Hector Zepeda
Octavio Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OPKO Pharmaceuticals LLC
Original Assignee
OPKO Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OPKO Pharmaceuticals LLC filed Critical OPKO Pharmaceuticals LLC
Priority to MX2013004975A priority Critical patent/MX2013004975A/en
Publication of WO2012061239A2 publication Critical patent/WO2012061239A2/en
Publication of WO2012061239A3 publication Critical patent/WO2012061239A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to influenza virus vaccines, and in particular to an influenza virus which has at least its hemagglutinin gene comprising a D222 mutation, and an oseltamivir resistant neuraminidase gene. In some embodiments the influenza virus vaccine further comprises a matrix protein comprising a mutation that increases specific immune response in humans. The virus is useful for production of vaccines against hypervirulent and oseltamivir-resistant influenza.
PCT/US2011/058336 2010-11-02 2011-10-28 Novel vaccines against pandemic influenza virus a/h1n1 Ceased WO2012061239A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2013004975A MX2013004975A (en) 2010-11-02 2011-10-28 Novel vaccines against pandemic influenza virus a/h1n1.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40930310P 2010-11-02 2010-11-02
US61/409,303 2010-11-02

Publications (2)

Publication Number Publication Date
WO2012061239A2 WO2012061239A2 (en) 2012-05-10
WO2012061239A3 true WO2012061239A3 (en) 2012-06-28

Family

ID=46025035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/058336 Ceased WO2012061239A2 (en) 2010-11-02 2011-10-28 Novel vaccines against pandemic influenza virus a/h1n1

Country Status (3)

Country Link
MX (1) MX2013004975A (en)
TW (1) TWI620819B (en)
WO (1) WO2012061239A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130140050A (en) * 2010-11-02 2013-12-23 헥토 마뉴엘 제페다 로페즈 Novel vaccines against the a/h1n1 pandemic flu virus
KR20150127586A (en) 2013-03-15 2015-11-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Influenza nucleic acid molecules and vaccines made therefrom
US12258540B2 (en) 2017-10-30 2025-03-25 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP4370152A1 (en) * 2021-07-16 2024-05-22 The Board Of Trustees Of The University Of Illinois Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175909A1 (en) * 2004-05-25 2009-07-09 Medimmune, Llc Influenza Hemagglutinin And Neuraminidase Variants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175909A1 (en) * 2004-05-25 2009-07-09 Medimmune, Llc Influenza Hemagglutinin And Neuraminidase Variants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 22 April 2010 (2010-04-22), STARICK. ET AL.: "Influenza A virus (A/Germany- BY/74/2009(H1N1)) segment 4 hemagglutinin (HA) gene, complete cds.", retrieved from http://www.ncbi.nlm.nih.gov/protein/ADF58349 accession no. M138501. *
DATABASE GENBANK 23 April 2010 (2010-04-23), retrieved from http://www.ncbi.nlm.nih.gov/nuccore/GU571155 accession no. U571155. *
MEMOLI ET AL.: "Rapid Selection of Oseltamivirand Peramivir-Resistant Pandemic H1N1 Virus during Therapy in 2 Immunocompromised Hosts.", CLIN INFECT DIS., vol. 50, no. 9, 1 May 2010 (2010-05-01), pages 1252 - 1255, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/nuccore/GU571155> *
POTDAR ET AL.: "Genetic Characterization of the Influenza A Pandemic (H1N1) 2009 Virus Isolates from India.", PLOS ONE, vol. 5, no. 3, 15 March 2010 (2010-03-15), pages E9693 *

Also Published As

Publication number Publication date
TWI620819B (en) 2018-04-11
TW201249996A (en) 2012-12-16
WO2012061239A2 (en) 2012-05-10
MX2013004975A (en) 2014-01-17

Similar Documents

Publication Publication Date Title
WO2012060678A3 (en) Novel vaccines against the a/h1n1 pandemic flu virus
WO2010077986A3 (en) Production of influenza vaccines
NZ627796A (en) Influenza virus vaccines and uses thereof
WO2010036970A3 (en) Influenza vaccines, antigens, compositions, and methods
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
AU2013367751A8 (en) Nasal influenza vaccine composition
WO2011094358A9 (en) Influenza nucleic acid molecules and vaccines made therefrom
WO2013044203A3 (en) Novel influenza hemagglutinin protein-based vaccines
AU2011280259A8 (en) Influenza vaccine
EA201590860A1 (en) VARIANTS OF HEMAGGLUTININ AND NEURAMINIDASE OF THE SWIN SWIRUS VIRUS
WO2013043067A3 (en) Dna vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the h5 haemagglutinin of an influenza virus and use of the dna vaccine
EA201290897A1 (en) VACCINES FOR PANDEMIC FLU
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
WO2012061239A3 (en) Novel vaccines against pandemic influenza virus a/h1n1
PH12014500369A1 (en) Influenza h5 vaccines
MX343411B (en) Influenza hemagglutinin and neuraminidase variants.
WO2011138032A3 (en) Universal influenza vaccines and methods for their generation
WO2012058493A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
FR2962739B1 (en) MODIFIED VIRAL STRAINS AND METHOD FOR IMPROVING VACCINE SEED PRODUCTION OF INFLUENZA VIRUSES
MX2011011561A (en) Novel vaccines against the a/h1n1 pandemic flu virus.
Robertson et al. Prospects for controlling future pandemics of influenza
SG10201703245SA (en) Fragments of the pa subunit of rna dependent rna polymerase from pandemic influenza virus a 2009 h1n1, and their use
EP2636735A4 (en) RECOMBINANT VIRAL VIRUS HAVING A PROTEIN GENE OF HEMAGGLUTININ DERIVED FROM A NEW TYPE OF INFLUENZA VIRUS
EP2195019A4 (en) Method of eliciting an immune response against pandemic influenza virus
PH12012501712A1 (en) Vaccines and vaccine compositions, and methods for the manufacture thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11838587

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/004975

Country of ref document: MX

122 Ep: pct application non-entry in european phase

Ref document number: 11838587

Country of ref document: EP

Kind code of ref document: A2